# A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

> **NCT05094804** · PHASE1,PHASE2 · UNKNOWN · sponsor: **OncoResponse, Inc.** · enrollment: 172 (estimated)

## Conditions studied

- Cancer
- Tumor, Solid
- Malignant Neoplasm
- Metastatic Cancer
- Advanced Solid Tumor
- Non Small Cell Lung Cancer
- Melanoma
- Head and Neck Squamous Cell Carcinoma
- Leiomyosarcoma
- Liposarcoma

## Interventions

- **DRUG:** OR2805
- **DRUG:** Cemiplimab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT05094804
- **Lead sponsor:** OncoResponse, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-09
- **Primary completion:** 2024-04-15
- **Final completion:** 2024-08-15
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2023-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05094804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05094804, "A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT05094804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*